‘Major Gap’ in Many Randomized Controlled Trials of Major Depressive Disorder
Many depression trials exclude real-world patients, study finds: A new analysis presented at the 2025 European College of Neuropsychopharmacology Congress found that about one-third (1/3) of people with major depressive disorder would not qualify for most randomized controlled trials of antidepressants, revealing a major gap between research and real-world patients. Common exclusion factors included substance use disorder, prior suicide attempts, comorbid serious somatic disease and other psychiatric disorders.